يعرض 1 - 10 نتائج من 27 نتيجة بحث عن '"U. Scheuring"', وقت الاستعلام: 0.99s تنقيح النتائج
  1. 1
    دورية أكاديمية
    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

    المؤلفون: D. Planchard, N. Reinmuth, S. Orlov, J. R. Fischer, S. Sugawara, S. Mandziuk, D. Marquez-Medina, S. Novello, Y. Takeda, R. Soo, K. Park, M. McCleod, S. L. Geater, M. Powell, R. May, U. Scheuring, P. Stockman, D. Kowalski

    المساهمون: D.Planchard, N.Reinmuth, S.Orlov, J.R.Fischer, S.Sugawara, S.Mandziuk, D.Marquez-Medina, S.Novello, Y.Takeda, R.Soo, K.Park, M.McCleod, S.L.Geater, M.Powell, R.May, U.Scheuring, P.Stockman, D.Kowalski

    مصطلحات موضوعية: ARCTIC, durvalumab, immunotherapy, metastatic non-small-cell lung cancer, tremelimumab

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32201234; info:eu-repo/semantics/altIdentifier/wos/WOS:000529333600008; volume:31; issue:5; firstpage:609; lastpage:618; numberofpages:///; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2318/1734181Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85082433085

    الإتاحة: https://doi.org/10.1016/j.annonc.2020.02.006Test
    http://hdl.handle.net/2318/1734181Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.

    المؤلفون: M.C. Garassino, K.H. Lee, F. Liu, Byoung Chul Cho, Jeffrey Gary Schneider, Zsolt Papai-Szekely, U. Scheuring, T. Van Ngoc, Naiyer A. Rizvi, Frances A. Shepherd, Sarayut Lucien Geater, Myung-Ju Ahn, Mario Ouwens, P. Thiyagarajah, Solange Peters, Niels Reinmuth, Delyth Clemett, Alexander Luft

    مصطلحات موضوعية: Oncology, Hematology

    العلاقة: url:https://www.openaccessrepository.it/communities/itmirrorTest; https://www.openaccessrepository.it/record/100517Test

    الإتاحة: https://doi.org/10.1093/annonc/mdz094.003Test
    https://www.openaccessrepository.it/record/100517Test

    View record in BASE

    أضف إلى المفضلة
  3. 3
    A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

    المؤلفون: Katie Quinn, Jiabu Ye, M. Kuziora, Philip Z Brohawn, F. Liu, Naiyer A. Rizvi, Rajiv Raja, Brandon Higgs, Han Si, Koustubh Ranade, Solange Peters, Kimberly C. Banks, U. Scheuring, Vikram Chand, Elena Helman

    المصدر: Clinical Cancer Research. 27:1631-1640

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Durvalumab, medicine.medical_treatment, First line, Treatment results, Circulating Tumor DNA, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Humans, Cutoff, 030212 general & internal medicine, Immune Checkpoint Inhibitors, Retrospective Studies, Chemotherapy, business.industry, Proportional hazards model, Prognosis, Clinical Trials, Phase III as Topic, Case-Control Studies, 030220 oncology & carcinogenesis, Mutation, Non small cell, business, Tremelimumab, Follow-Up Studies, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ba13a64c6502b7a31c5d422e234742Test
    https://doi.org/10.1158/1078-0432.ccr-20-3771Test


    أضف إلى المفضلة
  4. 4
    1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial

    المؤلفون: U. Scheuring, Matthew D. Hellmann, L. Poole, Solange Peters, Christopher Abbosh, M. Kuziora, A. Dey, Yashaswi Shrestha, Rajiv Raja, Zhongwu Lai, J.C. Barrett, Naiyer A. Rizvi

    المصدر: Annals of Oncology. 32:S989-S990

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Hematology, Immunotherapy, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business, DNA

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::afea72354f2b260c8c056bfc60034721Test
    https://doi.org/10.1016/j.annonc.2021.08.1866Test


    أضف إلى المفضلة
  5. 5
    PD-L1-Expression im Primärtumor vs. Metastase in Proben der Phase-III-Studie MYSTIC bei 1st-Line metastasiertem NSCLC

    المؤلفون: Jill Walker, Niels Reinmuth, Anne-Marie Boothman, V. Karwe, T. Wehler, Pralay Mukhopadhyay, A Luft, P. Thiyagarajah, Jessica Whiteley, M. de Wit, Naiyer A. Rizvi, Byoung Chul Cho, K.H. Lee, U. Scheuring, M. Scott, JC Ahn

    المصدر: 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b8f7213a87a8fd11706f544dac6ce7d1Test
    https://doi.org/10.1055/s-0039-3403150Test


    أضف إلى المفضلة
  6. 6
    Mutationen sind assoziiert mit einer Sensitivität oder Resistenz gegenüber einer Immuntherapie beim metastasierten NSCLC: eine Analyse aus der MYSTIC-Studie

    المؤلفون: M-J. Ahn, Vassiliki A. Papadimitrakopoulou, Han Si, N Reinmuth, John V. Heymach, K.H. Lee, A Rittmeyer, Solange Peters, Byoung Chul Cho, Brandon Higgs, F. Liu, Naiyer A. Rizvi, S. Wu, A Luft, M. Kuziora, U. Scheuring, Jiabu Ye

    المصدر: 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ee35959152314e00b4ceadb1031a8635Test
    https://doi.org/10.1055/s-0039-3403149Test


    أضف إلى المفضلة
  7. 7
    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

    المؤلفون: Edward B. Garon, Ki Hyeong Lee, Anne-Marie Boothman, Kazuhiko Nakagawa, Myung-Ju Ahn, Naiyer A. Rizvi, M. Cobo, Jeffrey Gary Schneider, Alexander Luft, Gilles Robinet, Michel M. van den Heuvel, David Vicente, Niels Reinmuth, Edward S. Kim, Scott J. Antonia, Vikram Chand, Sarayut Lucien Geater, Sarah B. Goldberg, Mystic Investigators, Vladimir Moiseyenko, Alexey Smolin, Solange Peters, Paul K. Stockman, U. Scheuring, Luping Zhao, Sylvestre Le Moulec, Ronald B. Natale, Byoung Chul Cho, Brandon Higgs, Rajiv Raja, Frances A. Shepherd

    المصدر: Jama Oncology, 6, 5, pp. 661-674
    Jama Oncology, 6, 661-674
    JAMA Oncol

    مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Durvalumab, Lung Neoplasms, medicine.medical_treatment, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Antibodies, Monoclonal, Humanized, Gastroenterology, law.invention, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Neoplasm Metastasis, Lung cancer, Aged, Aged, 80 and over, Chemotherapy, business.industry, Surrogate endpoint, Hazard ratio, Antibodies, Monoclonal, Correction, Middle Aged, medicine.disease, Chemotherapy regimen, Oncology, 030220 oncology & carcinogenesis, Female, business, Tremelimumab, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469d60b0beb513e4b153bebef9fa0110Test
    https://hdl.handle.net/2066/225429Test


    أضف إلى المفضلة
  8. 8
    ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

    المؤلفون: Juergen R. Fischer, M. Powell, Y. Takeda, Michael McCleod, Sergey Orlov, Silvia Novello, S. Mandziuk, Sarayut Lucien Geater, D. Marquez-Medina, David Planchard, R. May, Paul K. Stockman, Niels Reinmuth, Kwang Bo Park, Ross A. Soo, Dariusz M. Kowalski, U. Scheuring, S. Sugawara

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology. 31(5)

    مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Durvalumab, Lung Neoplasms, durvalumab, Antibodies, Monoclonal, Humanized, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, tremelimumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Adverse effect, ARCTIC, business.industry, metastatic non-small-cell lung cancer, Hazard ratio, immunotherapy, Antibodies, Monoclonal, Hematology, medicine.disease, Confidence interval, 030104 developmental biology, Oncology, Third line, 030220 oncology & carcinogenesis, Non small cell, business, Tremelimumab, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df21e614adbcd5facdd4e9ea97dfc2eTest
    https://pubmed.ncbi.nlm.nih.gov/32201234Test


    أضف إلى المفضلة
  9. 9
    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)

    المؤلفون: Frances A. Shepherd, Sarayut Lucien Geater, Gilles Robinet, Alexander Luft, Edward B. Garon, Ki Hyeong Lee, Myung-Ju Ahn, Niels Reinmuth, Jeffrey Gary Schneider, Naiyer A. Rizvi, Ronald B. Natale, Tran Van Ngoc, Nikunj Patel, Solange Peters, Byoung Chul Cho, Zsolt Papai Szekely, Sylvestre Le Moulec, F. Liu, Marina Chiara Garassino, U. Scheuring

    المصدر: Clinical Lung Cancer. 22:301-312.e8

    مصطلحات موضوعية: Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Durvalumab, medicine.medical_treatment, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Patient Reported Outcome Measures, Lung cancer, Aged, Chemotherapy, business.industry, Antibodies, Monoclonal, Repeated measures design, Immunotherapy, Middle Aged, medicine.disease, humanities, First line treatment, 030104 developmental biology, 030220 oncology & carcinogenesis, Quality of Life, Female, business, Tremelimumab, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c212f685398a1e9dafa6cd13fc526efTest
    https://doi.org/10.1016/j.cllc.2021.02.010Test


    أضف إلى المفضلة
  10. 10
    BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062)

    المؤلفون: Ana Tablante Nunes, Rachel Dougherty, Hannah Dry, U. Scheuring, Vatsala Karwe, Peter Schmid

    المصدر: Journal of Clinical Oncology. 39:TPS1105-TPS1105

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Poor prognosis, Durvalumab, business.industry, medicine.medical_treatment, Immune checkpoint inhibitors, First line, chemistry.chemical_compound, Paclitaxel, chemistry, Internal medicine, medicine, Open label, business, Triple-negative breast cancer

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::3dd7da1ec746b331bf8e540779cbe4baTest
    https://doi.org/10.1200/jco.2021.39.15_suppl.tps1105Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث